Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: GAMCO Investors, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  ...

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Perion Network Ltd. (NASDAQ & TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced it plans to release its financial results for the first quarter 2026 prior to the opening of the financial markets on Wednesday, May 20, 2026. Tal Jacobson, CEO, and Elad Tzubery, CFO, will host a conference call to discuss the results on that day at 8:30 a.m. ET....

MORRISVILLE, N.C.--(BUSINESS WIRE)--Extreme Networks today released financial results for its third quarter of fiscal 2026 ended March 31, 2026....

CHARLOTTE, N.C.--(BUSINESS WIRE)--Hayward Holdings, Inc. (NYSE: HAYW) (“Hayward,” the “Company,” “we,” “us,” or “our”), a leading global specialty water management company focused on designing and manufacturing pool and outdoor living technology and industrial flow control products, today announced financial results for the first quarter of fiscal year 2026, ended March 28, 2026. Comparisons are to financial results for the prior-year first fiscal quarter. CEO COMMENTS “Hayward delivered an out...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene editing treatment for Duchenne muscular dystrophy (DMD), is being evaluated in the Phase 1...

SAN FRANCISCO--(BUSINESS WIRE)--Hightouch, the leader in data and AI for marketing, today announced a $150 million Series D financing led by Growth Equity at Goldman Sachs Alternatives and Bain Capital Ventures, valuing the company at $2.75 billion. Additional investors and strategic partners also participated in the round, including Iconiq Capital, Sapphire Ventures, Amplify Partners, Y-Combinator, and TD7, the venture capital arm of The Trade Desk. The company has grown more than 100% in each...

NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today reported financial results for the quarter ended March 31, 2026. $617.8 million quarterly revenues, an increase of 21.2% (17.5% on a constant currency basis) compared to prior year period $274.1 million quarterly international revenues, an increase of 29.4% (20.7% on a constant current basis) compared to prior year period $3.3 trillion average daily volume (“ADV”) for...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Yum! Brands, Inc. (NYSE: YUM) today reported results for the first quarter ended March 31, 2026. First-quarter GAAP EPS was $1.55 and first-quarter EPS excluding Special Items was $1.50, a 15% increase year-over-year. CHRIS TURNER COMMENTS Chris Turner, CEO, said "We delivered solid topline momentum to start the year, with our fundamentals as strong as ever. Taco Bell delivered an outstanding 8% same-store sales growth, meaningfully ahead of the QSR industry, b...

ATLANTA--(BUSINESS WIRE)--Smith Douglas Homes Corp. (NYSE: SDHC) (“Smith Douglas” or the “Company”) today announced first quarter results for the three months ended March 31, 2026. Q1 2026 Results as compared to Q1 2025: Home closings decreased 7% to 624 Home closing revenue decreased 8% to $206.4 million Home closing gross margin of 19.6% compared to 23.8% Net new home orders increased 28% to 981 Backlog homes increased 10% to 869 Pretax income of $4.3 million compared to $19.6 million Earning...

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary   Q1 2026 % Change   $m Actual CER1 - Product Sales 14,386 12 7 - Alliance Revenue 825 29 26 Product Revenue 15,211 13 8 Collaboration Revenue 77 4 - Total Revenue 15,288 13 8 Reported EPS ($) 1.99 6 8 Core2 EPS ($) 2.58 4 5 Key performance elements for Q1 2026 (Growth numbers at constant exchange rates) Total Revenue up 8% to $15,288m, driven by double‑digit growth in Oncology and Rare Disease Core Operating profit incre...